Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia. | Lab Med | 2022 | 34791328 | PubTator, text mining | PubMed |
| Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. | Bone Marrow Transplant | 2022 | 34775480 | PubTator, text mining | PubMed |
| Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients. | Int J Hematol | 2022 | 34739701 | PubTator, text mining | PubMed |
| ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. | Blood Adv | 2022 | 34731884 | PubTator, text mining | PubMed |
| PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. | Blood | 2022 | 34695195 | PubTator, text mining | PubMed |
| Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. | J Cancer Res Clin Oncol | 2022 | 34674031 | PubTator, text mining | PubMed |
| Tumor suppressor function of WT1 in acute promyelocytic leukemia. | Haematologica | 2022 | 34670359 | PubTator, text mining | PubMed |
| KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia. | Blood Adv | 2022 | 34654054 | PubTator, text mining | PubMed |
| Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. | Blood Adv | 2022 | 34644397 | PubTator, text mining | PubMed |
| Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. | Blood Adv | 2022 | 34619772 | PubTator, text mining | PubMed |
| Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia. | Blood | 2022 | 34482400 | PubTator, text mining | PubMed |
Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). | J Cancer Res Clin Oncol | 2022 | 34480598 | PubTator, text mining | PubMed |
| Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. | Blood Adv | 2022 | 34448807 | PubTator, text mining | PubMed |
| A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors. | Mol Oncol | 2022 | 34407310 | PubTator, text mining | PubMed |
| Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention. | Drug Discov Today | 2022 | 34400351 | PubTator, text mining | PubMed |
| FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. | Haematologica | 2022 | 34348456 | PubTator, text mining | PubMed |
| Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. | Haematologica | 2022 | 34348451 | PubTator, text mining | PubMed |
| Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns. | Leukemia | 2022 | 34131280 | PubTator, text mining | PubMed |
| Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. | Blood | 2022 | 34111285 | PubTator, text mining | PubMed |
| LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. | Haematologica | 2022 | 33910331 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=45